Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine vs Agomelatine in MDD with Inadequate Response
NCT01488071Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jan 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Jan 2012; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01488071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488071.